Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.9% – Should You Sell?

Shares of Rapport Therapeutics (NASDAQ:RAPP) traded down 6.9% on Friday . The company traded as low as $15.07 and last traded at $15.54. 33,377 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 69,255 shares. The stock had previously closed at $16.69.

Rapport Therapeutics Price Performance

The firm’s 50 day simple moving average is $20.66.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Values First Advisors Inc. bought a new position in shares of Rapport Therapeutics in the third quarter worth about $31,000. BNP Paribas Financial Markets bought a new position in Rapport Therapeutics in the 3rd quarter valued at approximately $34,000. JPMorgan Chase & Co. acquired a new stake in Rapport Therapeutics in the third quarter valued at approximately $83,000. SG Americas Securities LLC bought a new stake in shares of Rapport Therapeutics during the third quarter worth $101,000. Finally, Sandia Investment Management LP acquired a new position in shares of Rapport Therapeutics during the second quarter worth $116,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.